Cellectis
Clinical-stage biotechnology company developing allogeneic (off-the-shelf) cell and gene therapies using an in-house gene editing platform and electroporation delivery system. The company combines TALEN-based gene editing, electroporation-based delivery, and internal GMP manufacturing to design and produce engineered CAR T product candidates and gene-editing approaches for hematopoietic stem/progenitor cells and other indications.
Industries
Nr. of Employees
medium (51-250)
Cellectis
8 rue de la Croix Jarry, 75013 Paris, France
Patents
Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells
US-12577581-B2
View Details
Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells
US-12577581-B2
View DetailsProducts
Allogeneic CAR T candidate targeting CD22 (UCART22 / lasme-cel)
Donor-derived CAR T product candidate engineered to target CD22 for relapsed or refractory B-cell acute lymphoblastic leukemia (BALLI-01 study).
Dual-target allogeneic CAR T (UCART20x22 / eti-cel)
Dual-target CAR T candidate engineered to recognize CD20 and CD22 for relapsed or refractory non-Hodgkin lymphoma (NatHaLi-01 study).
UCART123 (CD123-targeted allogeneic CAR T)
Previously pursued CD123-targeted allogeneic CAR T candidate for relapsed or refractory acute myeloid leukemia; program deprioritized to focus resources on core programs.
Licensed third-party product candidates (examples)
Technologies licensed to partners enabling development of additional allogeneic CAR T candidates (examples referenced include licensed programs directed to CD19, CD70 and other targets developed by partners).
Allogeneic CAR T candidate targeting CD22 (UCART22 / lasme-cel)
Donor-derived CAR T product candidate engineered to target CD22 for relapsed or refractory B-cell acute lymphoblastic leukemia (BALLI-01 study).
Dual-target allogeneic CAR T (UCART20x22 / eti-cel)
Dual-target CAR T candidate engineered to recognize CD20 and CD22 for relapsed or refractory non-Hodgkin lymphoma (NatHaLi-01 study).
UCART123 (CD123-targeted allogeneic CAR T)
Previously pursued CD123-targeted allogeneic CAR T candidate for relapsed or refractory acute myeloid leukemia; program deprioritized to focus resources on core programs.
Licensed third-party product candidates (examples)
Technologies licensed to partners enabling development of additional allogeneic CAR T candidates (examples referenced include licensed programs directed to CD19, CD70 and other targets developed by partners).
Services
In-house discovery, process development, GMP manufacturing, QC testing, cryostorage and supply for cell and gene therapy candidates.
Research collaborations, licensing of gene editing technologies and joint development programs with external pharmaceutical and biotech partners.
In-house discovery, process development, GMP manufacturing, QC testing, cryostorage and supply for cell and gene therapy candidates.
Research collaborations, licensing of gene editing technologies and joint development programs with external pharmaceutical and biotech partners.
Expertise Areas
- Allogeneic CAR T development
- Gene editing platform development
- Hematopoietic stem/progenitor cell (HSPC) gene modification
- GMP cell and gene therapy manufacturing
Key Technologies
- TALEN-class programmable nucleases
- Electroporation delivery systems
- Non-viral single-strand DNA donor templates (circularized ssDNA)
- TALE-based base editors
News & Updates
Regulatory designations granted by FDA and European Commission for UCART22 in the treatment of acute lymphoblastic leukemia.
Joint R&D collaboration covering multiple cell and gene therapy programs and an equity investment by AstraZeneca, with upfront and milestone payments and research cost support.
Conference posters and data describing intron editing for lineage-specific expression and circularized ssDNA donors to improve gene insertion in HSPCs.
Regulatory designations granted by FDA and European Commission for UCART22 in the treatment of acute lymphoblastic leukemia.
Joint R&D collaboration covering multiple cell and gene therapy programs and an equity investment by AstraZeneca, with upfront and milestone payments and research cost support.
Conference posters and data describing intron editing for lineage-specific expression and circularized ssDNA donors to improve gene insertion in HSPCs.